The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

The conversation surrounding health care reform has intensified in recent years, revealing deep divides in how we view personal responsibility, government intervention and public health ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Josh Gad has opened up for the first time about using GLP-1 medication for weight loss and his seesaw experience with the ...

Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...